| 발표일자: |
2015년 11월 6일(금) ~ 11월 8일(일) |
| 발표번호: |
P(e-poster)-055 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| 50세 미만의 결절맥락막혈관병증 환자의 특성과 6개월간의 치료성적 |
| 1: 건양의대 김안과병원 안과학교실, 2: 건양대학교 의과대학 안과학교실 |
| 황현지(1), 장영석(2), 김종우(1), 이태곤(1), 김철구(1), 조성원(1), 김재휘(1) |
|
목적 : To investigate the characteristics and 6-month treatment outcome of polypoidal choroidal vasculopathy (PCV) in patients aged <50 years.
방법 : This retrospective study included 22 eyes from 22 patients who were <50 years old and had been diagnosed with treatment naïve PCV. Analyses of treatment outcome were performed in eyes treated with anti-vascular endothelial growth factor (VEGF) therapy. Eyes that exhibited submacular hemorrhage of ≥1 disc diameter and involving the fovea were included in the hemorrhage group. The remaining eyes were included in the no-hemorrhage group. The baseline best-corrected visual acuity (BCVA) was compared with that at 6 months within each group.
결과 : The mean age of the 22 patients was 46.5 ± 1.8 (range, 43–49) years. Submacular hemorrhage was noted in 10 eyes (45.5%). Treatment outcome was analyzed in 18 eyes. A mean number of 2.9 ± 0.5 intravitreal anti-VEGF injections were administered during the 6-month follow-up period. In the no-hemorrhage group (n = 10), the BCVA at diagnosis and at 6 months was 0.55 ± 0.32 and 0.35 ± 0.22, respectively (P = 0.011). In the hemorrhage group (n = 8), the values were 0.99 ± 0.45 and 0.74 ± 0.63, respectively (P = 0.128).
결론 : A relatively high proportion of young PCV patients exhibited submacular hemorrhage at initial presentation. In those without submacular hemorrhage, intravitreal anti-VEGF therapy was found to be beneficial.
|
| |